Cover storyContinued Process Verification In Pharma: What Literature Shows
CPV theory is well understood, but literature shows execution is uneven, here's what real-world data reveals about running Stage 3 well.
Cover storyCPV theory is well understood, but literature shows execution is uneven, here's what real-world data reveals about running Stage 3 well.

SANOVO Phase III data back Tagrisso-Orpathys as first-line NSCLC therapy in China, triggering label expansion and manufacturing scale-up decisions.

Weave Bio's AI regulatory platform is live across 14 Takeda drug programs, setting a cross-portfolio benchmark for submission workflow automation.

AbbVie's etentamig cut progression risk by 60% across dual primary endpoints in Phase 3, signaling a likely BLA filing and bispecific scale-up challenge.

Cipla partners Qilu Pharmaceutical to commercialise a pembrolizumab biosimilar in the US, targeting Merck's Keytruda as patent exclusivity narrows.
Latest edition

Sep 28
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
